Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening

Journal of Clinical Sleep Medicine

Volumn 2, Issue 4, 2006, Pages 417-423

  Zammit, Gary K ^a,h   Corser, Bruce ^b   Doghramji, Karl ^c   Fry, June M ^d   James, Steven ^e   Krystal, Andrew ^f   Mangano, Richard M ^g  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Community Research Management Associates Inc ^*  (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e ALLERGAN INC   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g PFIZER INC   (United States)

^h Sleep Disorders Institute   (United States)

Author keywords

Hypnotic; Insomnia; PRN; Treatment; Zaleplon; Zolpidem

Indexed keywords

ANILIDE; ASCORBIC ACID; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; ESTROGEN; FLURAZEPAM; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIVITAMIN; PLACEBO; PROPIONIC ACID DERIVATIVE; PROTON PUMP INHIBITOR; SALICYLIC ACID; THYROID HORMONE; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; AGED; AROUSAL; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; HYPESTHESIA; INSOMNIA; MALE; METABOLIC DISORDER; NAUSEA; NERVOUSNESS; NIGHT SLEEP; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT EXAMINATION; SEDATION; SELF REPORT; SKIN DISEASE; SLEEP TIME; SLEEP WAKING CYCLE; SOMNOLENCE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VERTIGO; VOMITING; WAKEFULNESS;

EID: 33751118748     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.26657     Document Type: Article

References (29)

1. nd ed. Philadelphia: W.B. Saunders Company; 1994:483-5.
2. National Sleep Foundation. 2002 "Sleep In America" Poll. Available at: http://www.sleepfoundation.org/2002poll.html. Accessed: August 1, 2002.
3. Bixler EO, Kales A, Soldatos CR, Kales JD, Healey S. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 1979;136:1257-62.
4. Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills. Is increased mortality associated? Arch Gen Psychiatry 1979;36:103-16.
5. Klink ME, Quan SF, Kaltenborn WT, Lebowitz MD. Risk factors associated with complaints of insomnia in a general adult population: influence of previous complaints of insomnia. Arch Intern Med 1992;152:1634-7.
6. National Sleep Foundation, The Gallup Organization. Sleep in America: 1991. Princeton: The Gallup Organization; 1991.
7. Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depression and Anxiety 2003;18:163-76.
8. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. Sleep 1999;22:S347-53.
9. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84.
10. Simon GE, VonKorff M. Prevalence, burden and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-23.
11. Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R. An epidemiological study of insomnia among the Japanese general population. Sleep 2000;23:41-7.
12. Leger D, Guilleminault C, Dreyfus JP, Delahaye C, Paillard M. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res 2000;9:34-42.
13. Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep 1997;20:715-23.
14. Hohagen F, Käppier C, Schramm E, Riemann D, Weyerer S, Berger M. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551-4.
15. Roth T. New trends in insomnia management. J Psychopharmacol 1999;13:S37-40.
16. Consensus Conference. Drugs and insomnia. The use of medications to promote sleep. JAMA 1984;251:2410-4.
17. National Institutes of Health Consensus Development Conference Statement: the treatment of sleep disorders of older people March 26-28, 1990. Sleep 1991;14:169-77.
18. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 1994;48:25-40.
19. Kupfer DJ, Reynolds CFI. Management of insomnia. N Engl J Med 1997;336:341-6.
20. Rajput V, Bromley SM. Chronic insomnia: a practical review. Am Fam Physician 1999;60:1431-8.
21. Roth T, Hajak G, Üstün TB. Consensus for the pharmacological management of insomnia in the new millennium. Int J Clin Pract 2001;55:42-52.
22. Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000;23:1087-96.
23. Cluydts R, Peeters K, de Bouyalsky I, Lavoisy J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998;26:13-24.
24. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998;64:553-61.
25. Cluydts R. A 28-night evaluation of the efficacy, next-day effects, and withdrawal potential of zaleplon and zolpidem in outpatients with primary insomnia. Postgraduate Medicine: A Special Report-Insomnia: Treatment Options for the 21st Century. Minneapolis: McGraw- Hill Companies, Inc.; 2000:14-24.
26. Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000;23:17-21.
27. Carskadon MA, Dement WC, Miller MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986;9:519-24.
28. Garber M, Burke J, Farber R, Jochelson P, Campbell B. Residual effects of middle of the night dosing: a placebo-controlled crossover study of indiplon-IR, zolpidem, and zopiclone in healthy volunteers. Sleep 2004;27:A260.
29. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003:26;793-9.